All In Biotech

Drug Trial Radar · NCT00863538

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

An Open-label, Phase II Study of KPS-0373 in Patients With SCD

Last checked: Nov 19, 2026Latest source record: Feb 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Planned (sponsor's estimate)

Start

Not stated

Primary completion

Not stated

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

Conditions

  • Spinocerebellar Degeneration

Interventions

  • KPS-0373Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Scale for the assessment and rating of ataxia (SARA), ADL(Flow-FIM), Patient Improvement ImpressionTime frame: 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Japan

    Hokkaido Region, Japan

  • Japan

    Kansai Region, Japan

  • Japan

    Kanto Region, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.